US FDA. DRAFT GUIDANCE. BIOSIMILARITY AND INTERCHANGEABILITY : ADDITIONAL DRAFT Q&AS ON BIOSIMILAR DEVELOPMENT AND THE BPCI ACT. NOV 2020.